Compare Twist Bioscience Corp (TWST) vs Vanguard Short Term Corporate Bond ETF (VCSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Twist Bioscience Corp vs Vanguard Short Term Corporate Bond ETF — how do they compare? Twist Bioscience Corp trades at $126 (market cap $7.86B), while Vanguard Short Term Corporate Bond ETF trades at $78.6. The key difference: Twist Bioscience Corp is trading nearer its 52-week high, Vanguard Short Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| TWST | VCSH | |
|---|---|---|
Market Cap | $7.86B | — |
Sector | Health | Fixed Income |
52-Week High | $125.21 | $80.20 |
52-Week Low | $24.16 | $78.41 |
Enterprise Value | $7.79B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Twist Bioscience (TWST) trades at $125.16, up 1.66% today, with a bullish technical signal from moving averages but overbought RSI readings. Revenue growth is strong, with Q3 2026 revenue up 23% year-over-year to $118.4 million, though the company remains unprofitable with a net income margin of -31.66%. Recent news highlights a $300 million public offering and expansion in AI-driven drug discovery, fueling investor optimism.
The outlook is mixed: robust revenue growth and analyst buy ratings (78.57%) support upside, but persistent losses, high valuations (P/S of 17.73), and cash flow deficits pose risks. Investors should weigh the potential for EBITDA breakeven by fiscal 2027 against execution challenges in a competitive biotech landscape.
VCSH trades at $78.58, up 0.08% today, with a neutral technical signal overall. The ETF shows bearish moving averages but neutral oscillators, with RSI levels around 55-64 indicating no extreme conditions. Recent news highlights its competitive yield and low expense ratio compared to peers like ISTB, though some analysts downgrade it to 'Hold' due to tight credit spreads. Dividend payments remain consistent, with recent payouts around $0.29-$0.30 per share.
Outlook is cautious; VCSH offers stable income with minimal interest rate risk due to its short duration, but limited upside exists amid high yields and compressed spreads. Risks include credit spread widening and Fed policy shifts. Institutional activity is mixed, with some reducing stakes while others increase holdings, reflecting divergent views on short-term corporate bonds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →About Vanguard Short Term Corporate Bond ETF
VCSH tracks the Bloomberg U.S. 1-5 Year Corporate Bond Index, focusing on high-quality, investment-grade debt with short maturities. It is designed to offer higher income than Treasury bills with significantly lower interest rate sensitivity than intermediate or long-term bond funds.
Read more on VCSH →
